ASH 2024 – Galapagos turns Car-T manufacturing on its head
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
Jefferies 2024 – Cargo tries again with an old idea
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
Gilead’s multiple bets on fast Car production
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.
Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
